Form 8-K - Current report:
SEC Accession No. 0001438533-23-000050
Filing Date
2023-12-04
Accepted
2023-12-04 16:10:22
Documents
12
Period of Report
2023-11-30
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20231130.htm   iXBRL 8-K 41919
  Complete submission text file 0001438533-23-000050.txt   176818

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20231130.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20231130_lab.xml EX-101.LAB 26157
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20231130_pre.xml EX-101.PRE 13581
6 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20231130_htm.xml XML 2830
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 231463119
SIC: 2834 Pharmaceutical Preparations